Justin Petrone

New funds will allow the Estonian company to enter new markets in Europe and to invest in its pipeline of polygenic risk score-based tests.

The new tests, once developed, will be used for selecting patients who might best benefit from therapies for kidney disease, nonalcoholic steatohepatitis, and respiratory disease.

The test is already available commercially in Spain, and the company intends to next launch its offering in Italy, as it expands to other European markets.

Elypta is also developing a third test for the early detection of multiple cancers, which the company believes could eventually be used for routine cancer screening.

The assay underwent clinical validation at three centers in Singapore and 5,248 patients were ultimately screened using the test.

Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.

The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.